MARCELO BIGAL - 12 Aug 2024 Form 4/A Insider Report for Pacira BioSciences, Inc. (PCRX)

Role: Director
Signature: /s/ Kristen Williams, Attorney-in-Fact
Issuer symbol: PCRX
Transactions as of: 12 Aug 2024
Net transactions value: +$40,834
Form type: 4/A
Filing time: 13 Aug 2024, 08:43:41 UTC
Date Of Original Report: 12 Aug 2024
Previous filing: 13 Jun 2024
Next filing: 19 Aug 2024
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	PCRX	Common Stock	Purchase	$40,834	+3,400	+65%	$12.01	8,630	12 Aug 2024	Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.75 to $12.35, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 1.

Content

The price reported in Column 4 is a weighted average price. These shares were purchased in multiple transactions at prices ranging from $11.75 to $12.35, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range set forth in footnote 1.

Remarks:

This Amended Form 4 is being filed solely to correct typographical errors in Footnote 1 of the original Form 4 which inadvertently referenced shares being sold rather than purchased.